Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food

Vaccine

Volumn 31, Issue 41, 2013, Pages 4596-4602

  Rüedi Bettschen, Daniela ^a   Wood, Sherri L ^a   Gunnell, Melinda G ^a   West, C Michael ^a   Pidaparthi, Rama R ^b   Carroll, F Ivy ^b   Blough, Bruce E ^b   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Drug abuse; Hapten; Methamphetamine; Preclinical studies; Rats; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; METHAMPHETAMINE; METHAMPHETAMINE CONJUGATE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEEDING DISORDER; FOOD INTAKE; MALE; METHAMPHETAMINE DEPENDENCE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

THE METH-LIKE HAPTEN (S)-N-(2-(MERCAPTOETHYL)-6-(3-(2-(METHYLAMINO)PROPYL)PHENOXY)HEXANAMIDE; (+)-AMPHETAMINE; (+)-METHAMPHETAMINE; (+)-[2′,6′-(3)H(N)]-METHAMPHETAMINE; AMP; CYS; DRUG ABUSE; EQUILIBRIUM DISSOCIATION CONSTANT; FI; FIXED-INTERVAL SCHEDULE OF BEHAVIORAL REINFORCEMENT; FIXED-RATIO SCHEDULE OF BEHAVIORAL REINFORCEMENT; FR; HAPTEN; HSMO9; IC(KLH); IC(KLH)-CYS; IC(KLH)-SMO9; IMMUNOCYANIN MONOMERS DERIVED FROM NATIVE KLH; K(D); KEYHOLE LIMPET HEMOCYANIN; KLH; L-CYSTEINE; LC-MS/MS; LIQUID CHROMATOGRAPHY COUPLED TO TANDEM MASS SPECTROMETRY; MAB; MALEIMIDE ACTIVATED IMMUNOCYANIN END CAPPED WITH CYSTEINE; MCV; METH; METH-CONJUGATE VACCINE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; PRECLINICAL STUDIES; RAPID EQUILIBRIUM DIALYSIS; RATS; RED; THE METH-CONJUGATE VACCINE; VACCINE; [(3)H]-METH;

ANIMALS; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE;

EID: 84883598261     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.038     Document Type: Article

References (43)

1. Nicosia N., Pacula R.L., Kilmer B., Lundberg R., Chiesa J. The Economic Cost of Methamphetamine Use in the United States, 2005 2009, Rand Corporation, Santa Monica, CA.
2. Owens S., Atchley W., Hambuchen M., Peterson E., Gentry W. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord-DR 2011, 10:892-898.
3. Gentry W.B., Rüedi-Bettschen D., Owens S.M. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther 2010, 88:390-393.
4. Cho A.K. Ice: a new dosage form of an old drug. Science 1990, 249:631-634.
5. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001, 21:9414-9418.
6. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 2006, 63:90-100.
7. Richards J.R., Bretz S.W., Johnson E.B., Turnipseed S.D., Brofeldt B.T., Derlet R.W. Methamphetamine abuse and emergency department utilization. West J Med 1999, 170:198-202.
8. Albertson T.E., Derlet R.W., Van Hoozen B.E. Methamphetamine and the expanding complications of amphetamines. West J Med 1999, 170:214-219.
9. Brecht M.L., Mayrhauser von C., Anglin M.D. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs 2000, 32:211-220.
10. Byrnes-Blake K.A., Carroll F.I., Abraham P., Owens S.M. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol 2001, 1:329-338.
11. Carroll F.I., Blough B.E., Pidaparthi R.R., Abraham P., Gong P.K., Deng L., et al. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 2011, 54:5221-5228.
12. Peterson E.C., Laurenzana E.M., Atchley W.T., Hendrickson H.P., Owens S.M. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J Pharmacol Exp Ther 2008, 325:124-133.
13. Carroll F.I., Abraham P., Gong P.K., Pidaparthi R.R., Blough B.E., Che Y., et al. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 2009, 52:7301-7309.
14. Miller M.L., Moreno A.Y., Aarde S.M., Creehan K.M., Vandewater S.A., Vaillancourt B.D., et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry 2012, 1-8.
15. Shen X.Y., Kosten T.A., Lopez A.Y., Kinsey B.M., Kosten T.R., Orson F.M. Drug Alcohol. Depend 2013, 129:41-48.
16. Duryee M.J., Bevins R.A., Reichel C.M., Murray J.E., Dong Y., Thiele G.M., et al. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009, 27:2981-2988.
17. Pravetoni M., Le Naour M., Harmon T.M., Tucker A.M., Portoghese P.S., Pentel P.R. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther 2012, 341:225-232. Epub2012Jan18.
18. Pravetoni M., Raleigh M.D., Le Naour M., Tucker A.M., Harmon T.M., Jones J.M., et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 2012, 30:4617-4624. Epub2012May11.
19. Satoskar S.D., Keyler D.E., LeSage M.G., Raphael D.E., Ross C.A., Pentel P.R. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 2003, 3:957-970.
20. Kinsey B.M., Jackson D.C., Orson F.M. Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009, 87:309-314.
21. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S.C., Shields J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20:1196-1204.
22. Martell B.A., Mitchell E., Poling J., Gonsai K., Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58:158-164.
23. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PloS One 2008, 3:e2547.
24. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005, 35:2031-2040.
25. Miller J.S., Curtsinger J., Berthold M., Malvey K., Bliss R.L., Le C.T., et al. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clin Immunol 2005, 117:144-151.
26. Carrera M.R., Ashley J.A., Wirsching P., Koob G.F., Janda K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 2001, 98:1988-1992. Epub2001Feb6.
27. Carrera M.R., Meijler M.M., Janda K.D. Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem 2004, 12:5019-5030.
28. Li Q-Q., Luo Y-X., Sun C-Y., Xue Y-X., Zhu W-L., Shi H-S., et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 2011, 119:1271-1281.
29. Kantak K.M., Collins S.L., Lipman E.G., Bond J., Giovanoni K., Fox B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 2000, 148:251-262.
30. Kantak K.M., Collins S.L., Bond J., Fox B.S. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology 2001, 153:334-340.
31. Moreno A.Y., Janda K.D. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 2009, 92:199-205.
32. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89:392-399. Epub2011Jan26.
33. Slovin S.F., Keding S.J., Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005, 83:418-428.
34. Peterson E.C., Gunnell M., Che Y., Goforth R.L., Carroll F.I., Henry R., et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 2007, 322:30-39.
35. Akera T., Cheng V.K. A simple method for the determination of affinity and binding site concentration in receptor binding studies. Biochim Biophys Acta 1977, 470:412-423.
36. Hendrickson H., Laurenzana E., Owens S.M. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J 2006, 8:E709-E717.
37. Segal D.S., Kuczenski R. Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 1987, 242:917-926.
38. Proksch J.W., Gentry W.B., Owens S.M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000, 292:831-837.
39. Pitas G., Laurenzana E.M., Williams D.K., Owens S.M., Gentry W.B. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 2006, 34:906-912.
40. Milesi-Hallé A., McMillan D.E., Laurenzana E.M., Byrnes-Blake K.A., Owens S.M. Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacol Biochem Behav 2007, 86:140-149.
41. Gentry W.B., Ghafoor A.U., Wessinger W.D., Laurenzana E.M., Hendrickson H.P., Owens S.M. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. Pharmacol Biochem Behav 2004, 79:751-760.
42. Moreno A.Y., Azar M.R., Warren N.A., Dickerson T.J., Koob G.F., Janda K.D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm 2010, 7:431-441.
43. Pinto V.V., Salanti A., Joergensen L.M., Dahlback M., Resende M., Ditlev S.B., et al. The effect of adjuvants on the immune response induced by a DBL4varepsilon-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine 2012, 30:572-579. Epub2011Nov26.